Patent · US Active

PDE9 inhibitors with imidazo triazinone backbone

US9850249B2 · kind B2 · utility

4Cited by
5References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 22, 2016
Grant dateDec 26, 2017
Priority date
Expiry dateNov 22, 2036

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P31/18
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.